In its SmPC (summaries of product characteristics), Ranbaxy states that there is a non-negligible risk of medical abortion treatment failure, as follows:
The non-negligible risk of failure, which occurs in 4.5 to 7.8% of the cases, makes the follow-up visit mandatory in order to check that abortion is complete.
The patient should be informed that surgical treatment may be required to achieve complete abortion.
Ranbaxy (UK) Limited is the manufacturer of Medabon, the mifepristone/misoprostol combination treatment provided by BPAS to its pills-by-post clients.
Percuity 